Contact: Chris Martin, IASLC Media Relations, email@example.com, 630.670.2745
[Singapore-- September 9, 2023] ⎯ Chief pathologist Fernando Lopez-Rios, MD, PhD was awarded the Mary J. Matthews Pathology/Translational Research Award today at the 2023 IASLC World Conference on Lung Cancer.
The Mary J. Matthews Pathology/Translational Research Award recognizes an IASLC scientist for lifetime achievement in pathology and translational research of thoracic malignancies. Dr. Matthews served as a senior investigator and pathologist at the National Cancer Institute’s Medical Oncology Branch. She was a pioneer in the foundation of the histologic subtypes of lung cancer and the relationship between those subtypes and the clinical course of lung cancer.
Fernando Lopez-Rios, MD, PhD is the Chief of Molecular Diagnostics viServices in the Department of Pathology at the University Hospital in Madrid. He received his medical degree and PhD from the Faculty of Medicine at Autonoma University and Complutense University respectively and completed his residency in Pathology at 12 de Octubre University Hospital in Madrid.
Dr. Lopez-Rios has also been the Director of the Therapeutic Targets Laboratory at HM Hospitales and a visiting researcher at Memorial Sloan Kettering Cancer Center in New York City. His main clinical and research expertise is in cancer biomarker testing, with a special interest in lung cancer and mesothelioma. He is also currently a member of the IASLC Pathology Committee.
About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2022.iaslc.org/.